About the Editors

Chief Editor: Alexia-Ileana Zaromytidou, PhD, Springer Nature, United States of America ORCID

Alexia completed her BSc in Molecular Biology at University College London, followed by a PhD in Biochemistry in the laboratory of Richard Treisman at the London Research Institute of Cancer Research UK (now the Francis Crick Institute) in London, UK. She carried out her postdoctoral research in the lab of Joan Massagué at Memorial Sloan Kettering Cancer Center in New York. She joined the Nature Cell Biology editorial team in 2010, championing cancer biology as a major field at the journal, and was later promoted to Chief Editor, overseeing the expansion of the journal’s scope and editorial team. After working on a publishing proposal for a new cancer-dedicated Nature journal in 2018, she took the helm of Nature Cancer as its launch Chief Editor in 2019. During her editorial career Alexia has handled thousands of manuscripts across preclinical, translational and clinical research and has contributed to the development of several editorial & publishing policies of the Nature Portfolio. She is an active member of the scientific community, having co-organized a large number of scientific conferences, and delivering numerous talks and workshops every year to advise researchers on matters pertaining to their work, best scientific practice and science policy. Alexia is based in New York.

Senior Editor: Lisa Hoffmann-Haas, PhD, Springer Nature, Germany

Email: lisa.haas@nature.com | X: @LisaHaas0107

Lisa obtained her master’s degree from the University of Vienna, during which she was trained in the laboratory of Jacqui Shields at the MRC Cancer Unit in Cambridge, UK. She then completed her PhD in the laboratory of Anna Obenauf at the Institute of Molecular Pathology (IMP) in Vienna, Austria. Her doctoral research was based on the intersection of targeted therapy and immunotherapy and focused on understanding the effects of acquired resistance to targeted therapy on the tumor microenvironment. She joined Nature Cancer in 2021 and is based in the Berlin office.

Senior Editor: Ioanna Pavlaki, PhD, Springer Nature, Germany

Email: ioanna.pavlaki@nature.com

Ioanna completed her Master´s and PhD degrees in Molecular Medicine at the University of Essex (UK), where she trained in the Molecular Oncology laboratory of Elena Klenova. Her PhD thesis focused on the effect of post-translational modifications of transcription factors on gene expression regulation. She then carried out postdoctoral work in the laboratory of Keith Vance at the University of Bath (UK) studying lncRNA biology and chromatin architecture. Subsequently, she worked as a postdoctoral research fellow in R-loop biology in the laboratory of Christof Niehrs, at the Institute of Molecular Biology (Mainz, Germany). She joined Nature Cancer in October 2021 and is based in the Berlin office.

Senior Editor: Eleni Skourti, PhD, Springer Nature, United Kingdom ORCID

Email: eleni .skourti@nature.com | X: @skourti_elena

Eleni obtained her master’s degree from the University of Athens, with her thesis focusing on the role of miRNAs in skin cancer. She completed her PhD at the Rayne Institute in King’s College London, where she developed tools to image miRNAs and to trace hypoxic events in breast cancer. Subsequently, she conducted post-doctoral research in the Telomere Stability group at the London Institute of Medical Sciences, Imperial College London, where she studied telomeric factors that drive mechanisms involved in the alternative lengthening of telomeres (ALT) in cancer cells. She then joined The FEBS Journal editorial team in 2021. Eleni joined Nature Cancer in November 2023 and is based in the London office.

Associate Editor: Julieta Alfonso, PhD, Springer Nature, Germany ORCID

Email: julieta.alfonso@nature.com

Julieta studied Biology and completed her PhD in Molecular Biology and Biotechnology in the lab of Prof. Alberto Carlos Frasch in Argentina. She moved to Germany to work as a postdoc in Prof. Hannah Monyer’s lab at the University Hospital Heidelberg, where she focused on postnatal neurogenesis in mammalian models. She established her group at the Department of Clinical Neurobiology, German Cancer Research Center (DKFZ) in 2014. Her team investigated molecular and cellular mechanisms involved in neural cell proliferation and migration in brain development and malignant growth. Specifically, her group focused on the interaction between the vascular and nervous systems in the developing brain and lipid metabolic pathways in glioblastoma. She joined Nature Cancer in 2024 and is based in Heidelberg, Germany.

Associate Editor: Tiffanie Chouleur, PhD, Springer Nature, United Kingdom ORCID

Email: tiffanie.chouleur@nature.com

Tiffanie obtained her PhD in Cell Biology and Pathophysiology from the University of Bordeaux, France and McGill University, Canada as part of a co-tutelle program. She studied the role of protein tyrosine phosphatases in the progression of glioblastoma and the modulation of tumor microenvironment. In parallel, Tiffanie worked on establishing signatures that predict recurrence in patients with IDH-mutant glioma using multi-omic datasets. She joined Nature Cancer in March 2024 and is based in the London office.

Senior Editor: Luca Danelli, PhD, Springer Nature, UK

Email: luca.danelli@nature.com

Luca did his PhD at the University of Udine (Italy), where he studied the interaction between mast cells and myeloid derived suppressor cells within the tumour microenvironment. After a first post-doctoral experience at the Inserm UMRS-1149- Paris Diderot University working on mast cells and renal diseases, Luca joined the Francis Crick Institute, where he worked on the characterization of CD4+ T differentiation and expression of immune checkpoint receptors in mouse models of viral infections and cancer. Luca started his editorial career at Nature Communications in 2019. He joined Nature Cancer in August 2024 as a Locum Senior Editor and is based in the London office.

Senior Editor: Vincenzo Giacco, PhD, Springer Nature, United Kingdom ORCID

Email: vincenzo.giacco@nature.com | X: @Vin_Giacco

Vincenzo earned his master’s degree in medical biotechnologies from the University of Naples Federico II (Italy). In 2018, he completed his PhD in Neurobiology at the International School for Advanced Studies (Italy), where he researched neuroinflammation in spinal cord networks. He then pursued post-doctoral research at the Wolfson Centre for Age-Related Diseases at King's College London (UK), focusing on the modulation of the TRPA1 channel in glial cells related to demyelination, epilepsy, and ischemia. Vincenzo began his editorial career at eClinicalMedicine (part of The Lancet group) and joined Nature Cancer in September 2024, working out of the London office.

Associate Editor: Heathcliff Dorado Garcia, PhD, Springer Nature, Germany

Email: heathcliffdoradogarcia@nature.com

Heathcliff completed his Master's degree in Molecular Medicine at Charité University Medicine in Berlin, Germany. He then obtained his PhD at the Experimental and Clinical Research Center of the Max Delbrück Center, in Berlin. There, he studied therapeutic vulnerabilities in pediatric solid tumors in the context of DNA damage and replication stress. Later, he continued in the lab studying oncogene amplification in extrachromosomal circular DNAs in high-risk neuroblastoma. Heathcliff joined Nature Cancer as a Locum Associate Editor in September 2024 and is based in the Berlin office.

The Research Cross-Journal Editorial Team supports the Nature-branded research journals, with a focus on handling primary research manuscripts.
The Reviews Cross-Journal Editorial Team handles Research Briefing articles for the Nature-branded research journals.